Syracuse, NY, United States of America

Michael Politino


Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 26(Granted Patents)


Location History:

  • Fayetteville, NY (US) (1996)
  • Syracuse, NY (US) (1999 - 2014)

Company Filing History:


Years Active: 1996-2014

Loading Chart...
11 patents (USPTO):Explore Patents

Title: Michael Politino: Innovator in Pharmaceutical Chemistry

Introduction

Michael Politino is a notable inventor based in Syracuse, NY (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of inhibitors for dipeptidyl peptidase IV. With a total of 11 patents to his name, Politino's work has had a considerable impact on drug development.

Latest Patents

Among his latest patents is a process for preparing dipeptidyl peptidase IV inhibitors and intermediates. This innovative process involves the production of cyclopropyl-fused pyrrolidine-based inhibitors. The method employs a BOC-protected amine structure, which is prepared through a series of chemical reactions involving ammonium formate, nicotinamide adenine dinucleotide, dithiothreitol, and a partially purified enzyme concentrate. This approach allows for the efficient formation of the BOC-protected amine without the need for isolation.

Career Highlights

Michael Politino has worked with prominent companies in the pharmaceutical industry, including Bristol-Myers Squibb Company and AstraZeneca AB. His experience in these organizations has contributed to his expertise in drug formulation and development.

Collaborations

Throughout his career, Politino has collaborated with several professionals in the field, including Jason G. Chen and Paul M. Skonezny. These collaborations have further enhanced his research and innovation capabilities.

Conclusion

Michael Politino's contributions to pharmaceutical chemistry, particularly through his innovative patents, demonstrate his commitment to advancing medical science. His work continues to influence the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…